RayzeBio, Inc. (RYZB)

NASDAQ: RYZB · IEX Real-Time Price · USD
19.62
-0.16 (-0.81%)
At close: Sep 22, 2023, 4:00 PM
19.40
-0.22 (-1.12%)
After-hours: Sep 22, 2023, 7:10 PM EDT
-0.81%
Market Cap 1.14B
Revenue (ttm) n/a
Net Income (ttm) -70.31M
Shares Out 58.20M
EPS (ttm) -1.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 87,805
Open 19.78
Previous Close 19.78
Day's Range 19.52 - 20.92
52-Week Range 18.00 - 26.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Nov 15, 2023

About RYZB

RayzeBio is building a vertically integrated radiopharmaceutical therapeutics company with our lead program in a Phase 3 clinical trial. We have created a pipeline of multiple drug candidates in therapeutic areas with significant market opportunities. Our lead drug candidate, RYZ101, is designed to deliver a highly potent alpha particle radioisotope, Actinium 225, or Ac225, to tumors overexpressing SSTR2. We are enrolling in a registrational Phase 3 clinical trial of RYZ101 for the treatment of gasteroenteropancreatic neuroendocrine tumors, or ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 15, 2023
Employees 88
Stock Exchange NASDAQ
Ticker Symbol RYZB
Full Company Profile

Financial Performance

Financial Statements

News

RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN DIEGO--(BUSINESS WIRE)--RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the closing o...

4 days ago - Business Wire

RayzeBio stock opens with a big gain, to push valuation up to $1.4 billion

Investors cheered RayBio Inc. as it debuted on Wall Street, as the California-based radiopharmaceutical company's stock RYZB, +39.13% opened 38.9% above the initial public offering price. The company ...

8 days ago - Market Watch

RayzeBio valued at nearly $1 billion as upsized IPO prices at top of expected range

RayzeBio Inc. RYZB, has secured a near-$1 billion market valuation, as the California-based radiopharmaceutical company's upsized initial public offering priced at the top end of the expected range. T...

8 days ago - Market Watch

RayzeBio, Inc. Announces Pricing of Upsized $311 Million Initial Public Offering

SAN DIEGO--(BUSINESS WIRE)--RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the pricing o...

9 days ago - Business Wire

RayzeBio sets IPO terms, to be valued at up to $1 billion

RayzeBio Inc. RYZB, has set terms for its initial public offering, as the California-based radiopharmaceutical company with a tumor treatment in a Phase 3 trial looks to raise up to about $238.2 milli...

12 days ago - Market Watch

RayzeBio Appoints Christy Oliger to its Board of Directors

SAN DIEGO--(BUSINESS WIRE)--RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, appointed Christy Oliger to its board of dir...

25 days ago - Business Wire

RayzeBio IPO Registration Document (S-1)

RayzeBio has filed to go public with an IPO on the NASDAQ.

4 weeks ago - SEC